The cardiac arrhythmia suppression trial: implications for antiarrhythmic drug development.
Pratt
C M
CM
Department of Internal Medicine, Baylor College of Medicine, Houston, TX.
Moye
L
L
D000813:Anilides / Q000494:pharmacology / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards*; D004341:Drug Evaluation; D016700:Encainide; D005424:Flecainide / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D010865:Pilot Projects; D013997:Time Factors
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D005424:Flecainide; D016700:Encainide